Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02145182
Recruitment Status : Completed
First Posted : May 22, 2014
Last Update Posted : September 13, 2017
CTI Clinical Trial and Consulting Services
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : November 2016
  Actual Study Completion Date : November 2016

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 November 28, 2017
December 21, 2017
2 January 15, 2018
February 12, 2018
3 June 29, 2018
July 24, 2018
4 December 3, 2018